Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, \[11C\]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
Age range
55 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Timeframe: Visit 4 (1-4 weeks after LP)
Total Rapid Eye Movement (REM) Duration (Min)
Timeframe: Visit 3 (1-4 weeks after Visit 2)
Percentage of Time Spent in REM Sleep
Timeframe: Visit 3 (1-4 weeks after Visit 2)
REM Sleep Continuity
Timeframe: Visit 3 (1-4 weeks after Visit 2)
Number of sleep spindles that occur per minute during the N2 stage of sleep (N2 Spindle Density)
Timeframe: Visit 3 (1-4 weeks after Visit 2)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Timeframe: Visit 3 (1-4 weeks after Visit 2)
Mean picture test response time
Timeframe: Visit 3 (1-4 weeks after Visit 2)
Percentage of Correct Responses on the picture test
Timeframe: Visit 3 (1-4 weeks after Visit 2)